G7 Acetabular System with Vivacit-E or Longevity Liner PMCF Study

Not Applicable

Recruiting

• Conditions: Rheumatoid Arthritis of Hip; Osteoarthritis, Hip; Fractures, Hip; Avascular Necrosis of Hip; Osteoarthritis of Hip; Fracture of Hip; Total Hip Arthroplasty; Degenerative Joint Disease of Hip
• Interventions: Device: Vivacit-E and Longevity (HXLPE) Liners

• Registration Number: NCT04754087
• Lead Sponsor: Zimmer Biomet

Brief Summary

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.

Detailed Description

The primary endpoint is defined by the survival of the implant system at 10 years, which is based on removal or intended removal of the study device and will be determined using Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to either implant or instrumentation should be specified.

The secondary endpoints are the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs) as well as radiographic outcomes (if available).

Study Timeline

• Study First Submitted: 2021-01-25
• Study First Submitted QC: 2021-02-12
• Study First Posted: 2021-02-15
• Study Start: 2021-07-07
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-22
• Last Update Posted: 2024-10-24
• Primary Completion: 2033-12-31
• Study Completion: 2033-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patient must be a legal adult who has reached full skeletal maturity.
• Patient must be treated for one of the following indications:
• Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
• Rheumatoid arthritis
• Correction of functional deformity
• Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
• Revision procedures where other treatment or devices have failed
• Patient must be able and willing to complete the protocol required follow-up visits.
• Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB/EC) approved informed consent.

Exclusion Criteria

• Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.
• Patient has a metabolic disorder that may impair bone formation.
• Patient has osteomalacia.
• Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.
• Patient has rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.
• Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease
• Patient is a prisoner.
• Patient is a current alcohol or drug abuser.
• Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.
• Patient is pregnant.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
G7 Shell with Vivacit-E and Longevity Highly Crosslinked Polyethylene Liners	Vivacit-E and Longevity (HXLPE) Liners	Up to 300 hips globally will be implanted with a G7 Shell and either the Vivacit-E or Longevity Liner. The liner used by each site will be identified at start-up.

Primary Outcome Measures

Name	Time	Method
Adverse Event (safety)	At 10 years	Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.
Survival of the study device (liner); whether or not it is still implanted in the subject	At 10 years	Survivorship will be based on revision or intended revision of the study device (liner).

Secondary Outcome Measures

Name	Time	Method
Pain and Function using Modified Harris Hip Score	At 10 years	Pain and function will be measured using the Modified Harris Hip Score self assessment. The overall score runs from 0-100 with 100 representing the best outcome.
Patient Quality of Life using EQ-5D-5L Descriptive System	At 10 years	Perceived qualify of life will be measured using the EQ-5D-5L Descriptive System - comprises mobility, self care, usual activities, pain/discomfort, anxiety/depression. Each question in this section has an overall score of 1-5 with 1 representing the best health.
Pain and Function using Oxford Hip Score	At 10 years	Pain and function will be measured using the Oxford Hip Score self assessment. The overall score runs from 0-48 with 48 representing the best outcome.
Patient Quality of Life using EQ-5D-5L EQ visual analogue scale	At 10 years	Perceived qualify of life will be measured using the EQ visual analogue scale (EQ VAS) - records the respondent's self-rated health on a vertical, visual analogue scale. This section has an overall score of 0-100 with 100 representing the best health.

Trial Locations

Locations (11)

Colorado Joint Replacement; 🇺🇸 Denver, Colorado, United States

South Bend Orthopaedics; 🇺🇸 South Bend, Indiana, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Slocum Center for Orthopedics & Sports Medicine; 🇺🇸 Eugene, Oregon, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States

University of Utah Health; 🇺🇸 Salt Lake City, Utah, United States

Copenhagen University Hospital Hvidovre; 🇩🇰 Hvidovre, Denmark

Zuyderland Hospital; 🇳🇱 Geleen, Netherlands

OCON Hengelo; 🇳🇱 Hengelo, Netherlands

Skane University Hospital; 🇸🇪 Lund, Sweden

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust Royal Bournemouth Hospital; 🇬🇧 Bournemouth, UK, United Kingdom